62847-55-6

Upstream product

• 51834-15-2 3-nitropropionic acid chloride 
• 95-50-1 1,2-dichloro-benzene 
• 35857-66-0 3-chloro-1-(3,4-dichlorophenyl)propan-1-one 

Downstream Products

• 1206765-31-2 1-(3,4-dichloro-phenyl)-3-nitro-propan-1-one O-methyl-oxime 
• 56045-67-1 3-chloro-5-(3,4-dichloro-phenyl)-isoxazole 

Relevant academic research and scientific papers

CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.